DPP4 and hydrops fetalis: A recent pooled analysis illustrates that DPP-4 inhibitors do not increase the HF risk among T2DM patients with a previous history of HF, but they increased this risk among patients without history of HF (HR 1.21, 95% CI 1.04–1.41, p = 0.01), possibly because nearly all studied subjects had established CVD (280).